Fairvalue-Calculator Fairvalue-Calculator
EN DE

HOOKIPA Pharma Inc (HOOK) Fair Value & Analysis

Healthcare · US · Market cap $14.2M

Price$1.15
Fair Value$3.25
Upside+182.6%
Quality95/100
Evidence: Low Range $2.14 – $4.06

Fair value as of: Jun 25, 2026

Analysis

HOOKIPA Pharma Inc (HOOK) currently trades at $1.15, while our model-based Fair Value estimate is $3.25 — implying the stock looks roughly 182.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collabor…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is HOOKIPA Pharma Inc (HOOK) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $3.25 versus a price of $1.15 — about +183% (undervalued). Model-based estimate, not financial advice.
What is the fair value of HOOK?
Our 21-model fair value for HOOKIPA Pharma Inc is $3.25 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.15.
What is the quality score of HOOK?
HOOKIPA Pharma Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.